The withdrawal of drugs from the market as a result of post-authorisation pharmacovigilance

The withdrawal of drugs from the market as a result of post-authorisation pharmacovigilance

Subject of study. Post-authorisation pharmacovigilance enables the continuous updating of knowledge about adverse effects of medicinal products used in everyday clinical practice. As a result, new information emerges that may change the current positive safety assessment of the drug and contributes...

Full description

Bibliographic Details
Main Author:	Łukasz Dobrek
Format:	Article
Language:	Polish
Published:	Polish Pharmaceutical Society 2022-08-01
Series:	Farmacja Polska
Subjects:	clinical trials pharmacovigilance adverse drug reactions withdrawal of a medicinal product from the pharmaceutical market
Online Access:	https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2022%2F6%2F01_OG_Leki_wycofane_n.pdf

Similar Items

An evidence-based approach to the post-marketing withdrawal of medicinal products because of adverse reactions
by: Onakpoya, I
Published: (2017)

Evaluation of Pharmacovigilance System in Iran
by: Malahat Khalili, et al.
Published: (2022-07-01)

Pharmacovigilance on cannabidiol as an antiepileptic agent
by: Ilaria Ammendolia, et al.
Published: (2023-02-01)

The pharmacovigilance of psychoactive medications in Brazil
by: Elisaldo Luiz de Araújo Carlini, et al.
Published: (2003-10-01)

SIGNIFICANCE OF PHARMACOVIGILANCE AND ITS CLINICAL IMPLICATIONS
by: Susanta Kumar Bandyopadhyay, et al.
Published: (2016-12-01)

Perspective of undergraduate health-care students on adverse drug reaction and pharmacovigilance
by: Ahmed Atia, et al.
Published: (2023-01-01)

Current status and future prospects of pharmacovigilance in Pakistan
by: Rabia Hussain, et al.
Published: (2019-12-01)

Pharmacovigilance, hémovigilance, vaccinovigilance, tératovigilance… : quelles retombées imprévues pour les patients, les intervenants de santé et les systèmes de soins ?
by: Thierry Buclin, et al.

Topical Issues of Drug Safety, Possibilities of Improving of Pharmacovigilance
by: M. V. Zhuravleva, et al.
Published: (2019-09-01)

Problematic aspects of participation of pharmacists in the system of pharmacovigilance in Russia
by: E. N. Tkhoseva, et al.
Published: (2022-06-01)

IS THE PATIENT PARTNERSHIP INFORMATIVE IN PHARMACOVIGILANCE?
by: Yu. V. Muravyev
Published: (2017-09-01)

Evaluating drug withdrawal syndrome risks through food and drug administration adverse event reporting system: a comprehensive disproportionality analysis
by: Zheng Zhang, et al.
Published: (2024-07-01)

National strategy for the integration of pharmacovigilance in the Moroccan TB Control Program
by: Driss Soussi Tanani, et al.
Published: (2017-01-01)

THE AGGREGATE APPROACH TO THE PERIODIZATION OF THE FORMATION OF THE PHARMACOVIGILANCE SYSTEM
by: A. Е. Krasheninnikov
Published: (2019-01-01)

Pharmacovigilance study of spontaneous adverse drug reaction in a tertiary care centre
by: Wazid Ali, et al.
Published: (2022-01-01)

Challenges and experiences in establishing a zonal pharmacovigilance centre at Bangabandhu Sheikh Mujib Medical University: A 10-month journey
by: Elora Sharmin, et al.
Published: (2024-03-01)

Editorial: Leveraging pharmacovigilance data mining with “the patient” in mind
by: Maxine Gossell-Williams, et al.
Published: (2022-08-01)

Editorial: Pharmacoepidemiology and pharmacovigilance post-marketing drug safety studies
by: Zakir Khan, et al.
Published: (2024-08-01)

Knowledge, attitude, and practice study of pharmacovigilance in a dental teaching institute in Western India
by: Rashmi Venkatesh, et al.
Published: (2024-10-01)

Adverse drug reactions of macrolide therapy: analysis of spontaneous reports according to the Pharmacovigilance system
by: Skryabina A.A., et al.
Published: (2023-03-01)

Pharmacovigilance: the evolution of drug safety monitoring
by: Muhammad Akhtar Abbas Khan, et al.
Published: (2024-12-01)

DEBATABLE PROBLEMS OF PHARMACOVIGILANCE
by: Yu. V. Muravyev, et al.
Published: (2018-03-01)

Pharmacovigilance Activities in Maulana Azad Medical College and Associated Hospitals: A Step towards Patient Safety
by: Vandana Roy, et al.
Published: (2023-01-01)

Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
by: Maoxia Fan, et al.
Published: (2024-07-01)

Workshop on Adverse Drug Reaction Reporting, Pharmacovigilance and Its Implementation in Cancer Hospital in Nepal: An Event Report
by: Shrestha S, et al.
Published: (2020-01-01)

Editorial: Pharmacovigilance and drug repositioning research using pharmacoepidemiology
by: Yoshihiro Noguchi, et al.
Published: (2023-06-01)

Pharmacovigilance: Boon for the safety and efficacy of ayuvedic formulations
by: Anand Chaudhary, et al.
Published: (2010-01-01)

Deriving meaningful insights from clinical trial and postmarketing safety data: Perspectives from India
by: Anand Harugeri, et al.
Published: (2017-01-01)

Assessment of knowledge, practices, and barriers to pharmacovigilance among nurses at a teaching hospital, Ghana: a cross‑sectional study
by: Paa Kofi Tawiah Adu-Gyamfi, et al.
Published: (2022-08-01)

An educational intervention on attitudes in pharmacovigilance and adverse drug reactions reports among health-care professionals in a public hospital in the State of Mexico: An interventional and prospective assessment
by: Mariana Ortiz Reynoso, et al.
Published: (2023-09-01)

Analysis of adverse drug reactions reported to national pharmacovigilance center of Bhutan
by: Pelden Chejor, et al.
Published: (2021-06-01)

Features of International and Regional Pharmacovigilance Systems
by: Ksenia N. Koryanova, et al.
Published: (2020-09-01)

Sex and gender differences and pharmacovigilance: a knot still to be untied
by: Liberata Sportiello, et al.
Published: (2024-04-01)

Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases
by: Xianyu Dai, et al.
Published: (2025-01-01)

Pharmacovigilance systems for safety monitoring of herbal medicines: assessment of the national regulatory authority, manufacturers and marketing authorisation holders in Tanzania
by: Alambo K. Mssusa, et al.
Published: (2025-12-01)

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS)
by: Weidong Zhang, et al.
Published: (2025-01-01)

Safety Profile of Biological Drugs in Clinical Practice: A Retrospective Pharmacovigilance Study
by: Elaaf Fadhil Hassan, et al.
Published: (2022-06-01)

Assessment of knowledge, attitude, and practice of pharmacovigilance and materiovigilance among oral health practitioners in India
by: Lucky Yadav, et al.
Published: (2024-01-01)

Comparative Analysis of Adverse Drug Reactions Associated with Fluoroquinolones and Other Antibiotics: A Retrospective Pharmacovigilance Study
by: Alshareef H, et al.
Published: (2025-02-01)

Adverse drug reaction signals mining comparison of amiodarone and dronedarone: a pharmacovigilance study based on FAERS
by: Ye Xu, et al.
Published: (2024-10-01)